Friday, August 11, 2023
Corium and Lotus Pharmaceuti announced that they have entered into an exclusive collaboration and licence agreement for ADLARITY® (donepezil transdermal system), an innovative Alzheimer’s dementia treatment, in ten markets across Asia.
Under the terms of the agreement, Lotus seems to have exclusive rights to commercialise ADLARITY® in the mentioned countries, and they will also be responsible for handling the regulatory approval process in those countries. The applicable territories include Taiwan, South Korea, Hong Kong, Indonesia, Malaysia, Myanmar, Philippines, Singapore, Thailand, and Vietnam.
This partnership marks a significant achievement in the development and delivery of innovative therapies aimed at offering healthcare professionals essential treatment choices for patients, as well as their families and caregivers.
ADLARITY®, with its distinctive approach, offers a notable advancement in care that has the potential to greatly enhance the quality of life for individuals affected by Alzheimer's disease. ADLARITY® has received approval from the U.S. Food and Drug Administration (FDA) for use in the United States. It is the pioneering and sole once-weekly patch endorsed by the FDA for addressing mild, moderate, and severe dementia associated with Alzheimer's disease.
The transdermal system not only employs proprietary CorplexTM technology to ensure a consistent and gradual release of donepezil through the skin, but it also circumvents the need for passage through the gastrointestinal tract. This unique approach helps minimise the likelihood of gastrointestinal side effects.a
